Adicet Bio Balance Sheet Health
Financial Health criteria checks 5/6
Adicet Bio has a total shareholder equity of $235.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $268.8M and $33.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$224.07m |
| Equity | US$235.11m |
| Total liabilities | US$33.73m |
| Total assets | US$268.84m |
Recent financial health updates
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?
Jul 12
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?
Dec 07Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?
Aug 07Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Apr 20Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation
Dec 20Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Jul 07Recent updates
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?
Jul 12Adicet Bio: Microcap With A High Risk To Reward Ratio
May 23Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate
Feb 01Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?
Dec 07Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?
Aug 07Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Apr 20Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation
Dec 20Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio
Oct 17Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?
Oct 04Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term
Aug 16Adicet Bio: A First Take
Jul 22Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Jul 07Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit
May 15We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate
Mar 18Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate
Feb 09Adicet: Promising 2021 Therapeutic Initiations, Cash Of $108 Million, And New Management
Dec 28Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Dec 16Financial Position Analysis
Short Term Liabilities: ACET's short term assets ($228.4M) exceed its short term liabilities ($17.9M).
Long Term Liabilities: ACET's short term assets ($228.4M) exceed its long term liabilities ($15.8M).
Debt to Equity History and Analysis
Debt Level: ACET is debt free.
Reducing Debt: ACET has no debt compared to 5 years ago when its debt to equity ratio was 5.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACET has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ACET has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.